Exelixis: NCCN Change Supports Broader Use Of Cabometyx In Kidney Cancer

 
• By Emily Hayes
  
Helping Hand_169455167_1200.jpg
Updated practice guidelines give cabozantinib a boost in kidney cancer.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Scrip